Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ABIO · Entity 3781 | Chief Operating Officer | December 08, 2022 | December 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date December 08, 2022 · Filed December 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,730 |
Reported balance
After 2022-12-08 transaction · row 1
1 source rowRow 1 · 2022-12-08 · Grant · Acquired 40,000 · Balance 40,730 F1: Represents shares issued as restricted stock units (an "RSU") under the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The RSUs vest one year from December 8, 2022, subject to continuing employment with the Company through that date. In the event of a change in control of the Issuer or the grantee's involuntary termination without cause or by the grantee for good reason, 100% of the unvested RSUs shall become fully and immediately vested upon the closing date of such change in control or such involuntary termination date, respectively (to the extent such unvested RSUs have not yet then vested). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issued as restricted stock units (an "RSU") under the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The RSUs vest one year from December 8, 2022, subject to continuing employment with the Company through that date. In the event of a change in control of the Issuer or the grantee's involuntary termination without cause or by the grantee for good reason, 100% of the unvested RSUs shall become fully and immediately vested upon the closing date of such change in control or such involuntary termination date, respectively (to the extent such unvested RSUs have not yet then vested).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 08, 2022 Filed Dec 9, 2022 21:30 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060498 · doc4.xml · nonDerivative · entry 1 Keuer Thomas A · CIK 0001290482 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,730 F1 · shares: Represents shares issued as restricted stock units (an "RSU") under the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The RSUs vest one year from December 8, 2022, subject to continuing employment with the Company through that date. In the event of a change in control of the Issuer or the grantee's involuntary termination without cause or by the grantee for good reason, 100% of the unvested RSUs shall become fully and immediately vested upon the closing date of such change in control or such involuntary termination date, respectively (to the extent such unvested RSUs have not yet then vested). Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:32 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001209191-21-069963 · doc4.xml · derivative · entry 2 Keuer Thomas A · CIK 0001290482 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-12-14 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:47 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001209191-20-065028 · doc4.xml · derivative · entry 2 Keuer Thomas A · CIK 0001290482 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-12-21 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 48 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. Read SEC document |
| April 03, 2018 Filed Apr 3, 2018 21:01 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 482 | $0.50 | $241.72 |
DisclosureSEC source: 0001209191-18-023122 · doc4.xml · nonDerivative · entry 1 Keuer Thomas A · CIK 0001290482 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,153 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan"). Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 22:01 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 410 | $0.72 | $294.38 |
DisclosureSEC source: 0001209191-18-015077 · doc4.xml · nonDerivative · entry 1 Keuer Thomas A · CIK 0001290482 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,635 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan"). F2 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.7111 to $0.723. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased at each separate price. F3 · balance_after: Includes remaining 1,207 previously reported shares issued as RSUs under the Plan that vest on 4/2/18, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 12,428 previously reported shares of common stock owned. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 20:14 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 390 | $2.41 | $939.90 |
DisclosureSEC source: 0001209191-17-025619 · doc4.xml · nonDerivative · entry 1 Keuer Thomas A · CIK 0001290482 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,045 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan"). F2 · balance_after: Includes (i) remaining 1,222 previously reported shares issued as RSUs under the Plan that vest on 2/27/18, and (ii) remaining 1,207 previously reported shares issued as RSUs under the Plan that vest on 4/2/18, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 11,616 previously reported shares of common stock owned. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 22:11 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 465 | $2.61 | $1,213.65 |
DisclosureSEC source: 0001209191-17-015981 · doc4.xml · nonDerivative · entry 1 Keuer Thomas A · CIK 0001290482 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,435 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan"). F2 · balance_after: Includes (i) remaining 1,222 previously reported shares issued as RSUs under the Plan that vest on 2/27/18, and (ii) 2,414 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 10,799 previously reported shares of common stock owned. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:11 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 23,800 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001209191-17-015981 · doc4.xml · derivative · entry 2 Keuer Thomas A · CIK 0001290482 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,800 Underlying: Common Stock · 23,800 shares Expires 2027-02-26 F3 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Plan, 50% vesting upon achievement of certain pre-specified corporate milestone related to the outcome of the interim data analysis by that trial's Data and Safety Monitoring Board, and if the milestone is achieved, the remainder of the grant will vest on March 31, 2018, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. If the corporate milestone is not achieved, the Option will be cancelled. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 21:46 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 25,200 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-17-012752 · doc4.xml · derivative · entry 2 Keuer Thomas A · CIK 0001290482 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,200 Underlying: Common Stock · 25,200 shares Expires 2027-02-15 F2 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Plan, vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. Read SEC document |
| October 18, 2016 Filed Oct 18, 2016 20:30 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 483 | $2.45 | $1,183.83 |
DisclosureSEC source: 0001209191-16-146208 · doc4.xml · nonDerivative · entry 1 Keuer Thomas A · CIK 0001290482 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,900 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan") F2 · balance_after: Includes (i) remaining 2,443 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (ii) 2,414 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 10,043 previously reported shares of common stock owned. Read SEC document |
| September 20, 2016 Filed Sep 21, 2016 20:08 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 714 | $2.89 | $2,063.46 |
DisclosureSEC source: 0001209191-16-142260 · doc4.xml · nonDerivative · entry 1 Keuer Thomas A · CIK 0001290482 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,383 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan") F2 · price: The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $2.88 to $2.89. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes (i) remaining 1,429 previously reported shares issued as RSUs under the Plan that vests on 10/15/16, (ii) remaining 2,443 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (iii) 2,414 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 9,097 previously reported shares of common stock owned. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.